Perspective Therapeutics (CATX) Stock Forecast, Price Target & Predictions
CATX Stock Forecast
Perspective Therapeutics stock forecast is as follows: an average price target of $17.50 (represents a 44.03% upside from CATX’s last price of $12.15) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CATX Price Target
The average price target for Perspective Therapeutics (CATX) is $17.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $3.00. This represents a potential 44.03% upside from CATX's last price of $12.15.
CATX Analyst Ratings
According to 5 Wall Street analysts, Perspective Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CATX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Perspective Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Jeff Jones | Oppenheimer | $22.00 | $12.66 | 73.78% | 81.07% |
| Sep 25, 2024 | Nicole Germino | Truist Financial | $21.00 | $12.28 | 71.01% | 72.84% |
| Jul 25, 2024 | Alec Stranahan | Bank of America Securities | $24.00 | $12.82 | 87.21% | 97.53% |
| Jun 18, 2024 | Jeff Jones | Oppenheimer | $19.00 | $11.93 | 59.26% | 56.38% |
| Jun 14, 2024 | Gregory Renza | RBC Capital | $3.00 | $1.15 | 161.21% | -75.31% |
| May 15, 2024 | Jeff Jones | Oppenheimer | $2.00 | $1.57 | 27.39% | -83.54% |
The latest Perspective Therapeutics stock forecast, released on Oct 14, 2024 by Jeff Jones from Oppenheimer, set a price target of $22.00, which represents a 73.78% increase from the stock price at the time of the forecast ($12.66), and a 81.07% increase from CATX last price ($12.15).
Perspective Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 6 |
| Avg Price Target | $21.50 | $22.33 | $15.17 |
| Last Closing Price | $12.15 | $12.15 | $12.15 |
| Upside/Downside | 76.95% | 83.79% | 24.86% |
In the current month, the average price target of Perspective Therapeutics stock is $21.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 76.95% increase as opposed to Perspective Therapeutics's last price of $12.15. This month's average price target is down -3.72% compared to last quarter, and up 41.73% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 30, 2024 | Wedbush | - | Outperform | Initialise |
| Jun 18, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 14, 2024 | RBC Capital | - | Outperform | Initialise |
| May 09, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Apr 09, 2024 | B. Riley | Buy | Buy | Hold |
| Apr 01, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Perspective Therapeutics's last stock rating was published by Oppenheimer on Oct 14, 2024. The company gave CATX a "Outperform" rating, the same as its previous rate.
Perspective Therapeutics Financial Forecast
Perspective Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.50M | $1.83M | $1.83M | $1.72M | $2.50M | $2.91M | $2.82M | $2.56M | $2.71M | $2.60M | $2.36M | $2.38M | $2.28M | $2.88M | $2.21M |
| Avg Forecast | $2.06M | $2.05M | $2.03M | $2.02M | $2.01M | $2.00M | $1.99M | $66.67K | $132.22K | $131.63K | $183.48K | $368.80K | $1.85M | $2.60M | $2.06M | $2.84M | $3.11M | $2.95M | $2.49M | $2.70M | $2.43M | $2.40M | $2.85M | $2.70M | $2.54M | $2.30M | $2.12M | $1.93M | $1.93M |
| High Forecast | $2.06M | $2.05M | $2.03M | $2.02M | $2.01M | $2.00M | $1.99M | $66.67K | $132.22K | $137.45K | $183.72K | $368.80K | $2.23M | $2.60M | $2.06M | $2.84M | $3.11M | $2.95M | $2.49M | $2.70M | $2.43M | $2.40M | $2.85M | $2.70M | $2.54M | $2.30M | $2.12M | $1.93M | $1.97M |
| Low Forecast | $2.06M | $2.05M | $2.03M | $2.02M | $2.01M | $2.00M | $1.99M | $66.67K | $132.22K | $125.82K | $183.24K | $368.80K | $1.47M | $2.60M | $2.06M | $2.84M | $3.11M | $2.95M | $2.49M | $2.70M | $2.43M | $2.40M | $2.85M | $2.70M | $2.54M | $2.30M | $2.12M | $1.93M | $1.89M |
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.64% | 0.59% | 0.58% | 1.01% | 1.08% | 1.16% | 1.07% | 0.95% | 0.96% | 0.93% | 1.04% | 1.08% | 1.49% | 1.14% |
Perspective Therapeutics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $2.60M, with a low forecast of $2.60M, and a high forecast of $2.60M. CATX's average Quarter revenue forecast represents a 73.33% increase compared to the company's last Quarter revenue of $1.50M (Jun 23).
Perspective Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.08M | $-10.65M | $-3.10M | $-4.21M | $-2.11M | $-1.38M | $-1.64M | $-2.21M | $-1.09M | $-762.00K | $-859.00K | $-714.00K | $-1.19M | $-512.00K | $-864.00K |
| Avg Forecast | $-1.28M | $-1.27M | $-1.27M | $-1.26M | $-1.25M | $-1.24M | $-1.24M | $-41.46K | $-82.23K | $-81.87K | $-114.11K | $-229.37K | $-1.15M | $-1.62M | $-1.28M | $-1.77M | $-1.94M | $-1.83M | $-1.55M | $-1.68M | $-1.51M | $-1.49M | $-1.77M | $-1.68M | $-1.58M | $-1.43M | $-1.32M | $-1.20M | $-1.20M |
| High Forecast | $-1.28M | $-1.27M | $-1.27M | $-1.26M | $-1.25M | $-1.24M | $-1.24M | $-41.46K | $-82.23K | $-78.25K | $-113.96K | $-229.37K | $-911.78K | $-1.62M | $-1.28M | $-1.77M | $-1.94M | $-1.83M | $-1.55M | $-1.68M | $-1.51M | $-1.49M | $-1.77M | $-1.68M | $-1.58M | $-1.43M | $-1.32M | $-1.20M | $-1.18M |
| Low Forecast | $-1.28M | $-1.27M | $-1.27M | $-1.26M | $-1.25M | $-1.24M | $-1.24M | $-41.46K | $-82.23K | $-85.48K | $-114.26K | $-229.37K | $-1.39M | $-1.62M | $-1.28M | $-1.77M | $-1.94M | $-1.83M | $-1.55M | $-1.68M | $-1.51M | $-1.49M | $-1.77M | $-1.68M | $-1.58M | $-1.43M | $-1.32M | $-1.20M | $-1.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.65% | 6.02% | 1.60% | 2.29% | 1.36% | 0.82% | 1.08% | 1.49% | 0.62% | 0.45% | 0.54% | 0.50% | 0.90% | 0.43% | 0.72% |
undefined analysts predict CATX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Perspective Therapeutics's previous annual EBITDA (undefined) of $NaN.
Perspective Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.11M | $-371.00K | $-2.20M | $-3.93M | $-2.01M | $-1.21M | $-1.60M | $-2.24M | $-1.06M | $-745.00K | $-868.00K | $-713.00K | $-1.19M | $-545.00K | $-897.00K |
| Avg Forecast | $-89.78M | $-86.97M | $-84.17M | $-84.17M | $-96.32M | $-93.52M | $-86.97M | $-78.56M | $-66.63M | $-60.67M | $-57.71M | $-78.56M | $-126.25M | $-84.17M | $334.51M | $-28.06M | $-21.04M | $-21.04M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-37.41M | $-37.41M | $-37.41M | $-46.76M | $-56.11M | $-5.61M |
| High Forecast | $-89.78M | $-86.97M | $-84.17M | $-84.17M | $-96.32M | $-93.52M | $-86.97M | $-78.56M | $-66.63M | $-52.00M | $-57.71M | $-78.56M | $-126.25M | $-84.17M | $334.51M | $-28.06M | $-21.04M | $-21.04M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-37.41M | $-37.41M | $-37.41M | $-46.76M | $-56.11M | $-5.61M |
| Low Forecast | $-89.78M | $-86.97M | $-84.17M | $-84.17M | $-96.32M | $-93.52M | $-86.97M | $-78.56M | $-66.63M | $-66.45M | $-57.71M | $-78.56M | $-126.25M | $-84.17M | $334.51M | $-28.06M | $-21.04M | $-21.04M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-37.41M | $-37.41M | $-37.41M | $-46.76M | $-56.11M | $-5.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03% | 0.01% | 0.10% | 0.19% | 0.07% | 0.04% | 0.06% | 0.08% | 0.04% | 0.02% | 0.02% | 0.02% | 0.03% | 0.01% | 0.16% |
Perspective Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CATX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Perspective Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.98M | $7.83M | $2.99M | $3.91M | $2.24M | $2.27M | $2.32M | $2.60M | $1.97M | $1.76M | $1.75M | $1.65M | $1.94M | $1.96M | $1.74M |
| Avg Forecast | $2.18M | $2.17M | $2.16M | $2.14M | $2.13M | $2.12M | $2.11M | $70.66K | $140.15K | $139.52K | $194.47K | $390.90K | $1.96M | $2.76M | $2.18M | $3.01M | $3.30M | $3.13M | $2.63M | $2.86M | $2.57M | $2.54M | $3.02M | $2.86M | $2.69M | $2.44M | $2.24M | $2.05M | $2.05M |
| High Forecast | $2.18M | $2.17M | $2.16M | $2.14M | $2.13M | $2.12M | $2.11M | $70.66K | $140.15K | $145.69K | $194.73K | $390.90K | $2.37M | $2.76M | $2.18M | $3.01M | $3.30M | $3.13M | $2.63M | $2.86M | $2.57M | $2.54M | $3.02M | $2.86M | $2.69M | $2.44M | $2.24M | $2.05M | $2.09M |
| Low Forecast | $2.18M | $2.17M | $2.16M | $2.14M | $2.13M | $2.12M | $2.11M | $70.66K | $140.15K | $133.35K | $194.22K | $390.90K | $1.55M | $2.76M | $2.18M | $3.01M | $3.30M | $3.13M | $2.63M | $2.86M | $2.57M | $2.54M | $3.02M | $2.86M | $2.69M | $2.44M | $2.24M | $2.05M | $2.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.74% | 2.60% | 0.91% | 1.25% | 0.85% | 0.79% | 0.90% | 1.02% | 0.65% | 0.62% | 0.65% | 0.68% | 0.86% | 0.96% | 0.85% |
Perspective Therapeutics's average Quarter SG&A projection for Sep 23 is $2.76M, based on 1 Wall Street analysts, with a range of $2.76M to $2.76M. The forecast indicates a -53.95% fall compared to CATX last annual SG&A of $5.98M (Jun 23).
Perspective Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 3 | 7 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.04 | $-0.00 | $-0.02 | $-0.03 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.01 |
| Avg Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.30 | $-0.34 | $-0.33 | $-0.31 | $-0.28 | $-0.24 | $-0.22 | $-0.21 | $-0.28 | $-0.45 | $-0.30 | $1.19 | $-0.10 | $-0.07 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.20 | $-0.02 |
| High Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.30 | $-0.34 | $-0.33 | $-0.31 | $-0.28 | $-0.24 | $-0.19 | $-0.21 | $-0.28 | $-0.45 | $-0.30 | $1.19 | $-0.10 | $-0.07 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.20 | $-0.02 |
| Low Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.30 | $-0.34 | $-0.33 | $-0.31 | $-0.28 | $-0.24 | $-0.24 | $-0.21 | $-0.28 | $-0.45 | $-0.30 | $1.19 | $-0.10 | $-0.07 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.20 | $-0.02 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03% | 0.02% | 0.21% | 0.37% | 0.14% | 0.09% | 0.11% | 0.16% | 0.07% | 0.05% | 0.08% | 0.08% | 0.10% | 0.04% | 0.66% |
According to undefined Wall Street analysts, Perspective Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CATX previous annual EPS of $NaN (undefined).
Perspective Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FNA | Paragon 28 | $5.50 | $11.50 | 109.09% | Buy |
| NPCE | NeuroPace | $6.39 | $12.88 | 101.56% | Buy |
| CVRX | CVRx | $8.10 | $15.83 | 95.43% | Buy |
| OFIX | Orthofix Medical | $15.89 | $31.00 | 95.09% | - |
| LUNG | Pulmonx | $6.41 | $12.25 | 91.11% | Buy |
| SGHT | Sight Sciences | $5.95 | $10.25 | 72.27% | Hold |
| HYPR | Hyperfine | $1.00 | $1.60 | 60.00% | Buy |
| SIBN | SI-BONE | $12.81 | $20.00 | 56.13% | Buy |
| KIDS | OrthoPediatrics | $26.86 | $39.60 | 47.43% | Buy |
| CATX | Perspective Therapeutics | $12.15 | $17.50 | 44.03% | Buy |
| LIVN | LivaNova | $53.22 | $70.60 | 32.66% | Buy |
| SRDX | Surmodics | $38.38 | $39.50 | 2.92% | Buy |
CATX Forecast FAQ
Is Perspective Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Perspective Therapeutics (CATX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of CATX's total ratings.
What is CATX's price target?
Perspective Therapeutics (CATX) average price target is $17.5 with a range of $3 to $24, implying a 44.03% from its last price of $12.15. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Perspective Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CATX stock, the company can go up by 44.03% (from the last price of $12.15 to the average price target of $17.5), up by 97.53% based on the highest stock price target, and down by -75.31% based on the lowest stock price target.
Can Perspective Therapeutics stock reach $20?
CATX's highest twelve months analyst stock price target of $24 supports the claim that Perspective Therapeutics can reach $20 in the near future.
What is Perspective Therapeutics's current price target trend?
2 Wall Street analysts forecast a $21.5 price target for Perspective Therapeutics (CATX) this month, up 76.95% from its last price of $12.15. Compared to the last 3 and 12 months, the average price target increased by 83.79% and increased by 24.86%, respectively.
What are Perspective Therapeutics's analysts' financial forecasts?
Perspective Therapeutics's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $2.32M (high $2.32M, low $2.31M), average EBITDA is $-1.442M (high $-1.438M, low $-1.446M), average net income is $-293M (high $-284M, low $-299M), average SG&A $2.46M (high $2.46M, low $2.45M), and average EPS is $-1.044 (high $-1.013, low $-1.064). CATX's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $8.07M (high $8.07M, low $8.07M), average EBITDA is $-5.018M (high $-5.018M, low $-5.018M), average net income is $-358M (high $-358M, low $-358M), average SG&A $8.55M (high $8.55M, low $8.55M), and average EPS is $-1.277 (high $-1.277, low $-1.277).
Did the CATX's actual financial results beat the analysts' financial forecasts?
Based on Perspective Therapeutics's last annual report (Jun 2022), the company's revenue was $10.8M, beating the average analysts forecast of $10.01M by 7.87%. Apple's EBITDA was $-7.391M, beating the average prediction of $-6.224M by 18.75%. The company's net income was $-7.153M, missing the average estimation of $-112M by -93.63%. Apple's SG&A was $9.42M, missing the average forecast of $10.61M by -11.15%. Lastly, the company's EPS was $-0.0504, missing the average prediction of $-0.4 by -87.40%. In terms of the last quarterly report (Jun 2023), Perspective Therapeutics's revenue was $1.5M, missing the average analysts' forecast of $2.06M by -27.18%. The company's EBITDA was $-11.078M, beating the average prediction of $-1.281M by 764.67%. Perspective Therapeutics's net income was $-11.106M, missing the average estimation of $334.51M by -103.32%. The company's SG&A was $5.98M, beating the average forecast of $2.18M by 174.06%. Lastly, the company's EPS was $-0.0397, missing the average prediction of $1.19 by -103.33%